CD45BE-HSPC + CART-45 Cells

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.

Trial Details

NCT ID
NCT07451054
Phase
PHASE1
Sponsor
University of Pennsylvania
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CART-45 cells
  • CD45BE-HSPC
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • 1\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria
  • a. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:
  • i. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Ly…
  • 1\. Patients must have either failed/relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed/refractory disease …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →